Bangladesh declines to approve Chinese COVID vaccine trial by Sinovac Biotech

Sinovac Biotech Ltd in a letter on September 24 said the trial would be delayed unless the government provided funds, although the company was supposed to bear the costs as per an agreement, The Daily Star reported.;

Published On 2020-10-14 05:56 GMT | Update On 2020-10-14 05:56 GMT

Dhaka: The clinical trial of an experimental Chinese Covid-19 vaccine developed by Sinovac Biotech in Bangladesh is now uncertain as the health ministry refused to co-financing the initiative as requested by the Chinese drugmaker.

Sinovac Biotech Ltd in a letter on September 24 said the trial would be delayed unless the government provided funds, although the company was supposed to bear the costs as per an agreement, The Daily Star reported.

BDnews24 quoted Health Minister Zahid Maleque as saying that Sinovac should run the trial with their own money because that's what they said they would do when they had sought approval.

"(And) that's why they were given permission," he said.

"A country's job is done when it approves the clinical test of a vaccine. They never asked for co-funding when they sought approval for the trial. This is not a contract we have with the Chinese government. This is a private company and we cannot have a co-funding (arrangement) with a private company."

According to sources, it is gathered that around Taka 60 crore was the expenditure for conducting the trial on 4,200 volunteers.

The Health Minister has emphasised that Bangladesh will get the Sinovac vaccine, even if the trial does not go ahead as planned.

"We can buy the vaccine if it is approved. Sinovac will work with the WHO and it will provide different countries with the vaccine. We will also get it," Maleque said, adding that Bangladesh will also get early access to the vaccine and it will collaborate with India on developing it.

Article Source : ANI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

JnJ seeks indication extension of Akeega from EMA for adults with metastatic hormone-sensitive prostate cancer, HRR gene alterations

2025-07-06 07:00 GMT

Bangladesh declines to approve Chinese COVID vaccine trial by Sinovac Biotech

Sinovac Biotech Ltd in a letter on September 24 said the trial would be delayed unless the government provided funds, although the company was supposed to bear the costs as per an agreement, The Daily Star reported.;

Similar News

Indian pharma exports strong at USD 4.9 billion in April-May: Pharmexcil

Expert Panel Approves Post-Marketing Surveillance Study of Eculizumab (Soliris) by AstraZeneca in India

Emcure Pharma incorporates new wholly-owned subsidiary Emcure Wellness

JnJ seeks indication extension of Akeega from EMA for adults with metastatic hormone-sensitive prostate cancer, HRR gene alterations

Govt Panel Proposes Braille Cards, Voice-Enabled QR Codes on Medicine Packs to Aid Visually Impaired

AstraZeneca Imfinzi approved in EU for muscle-invasive bladder cancer

Pfizer's Abrocitinib Phase III Data Accepted by CDSCO Expert Committee

COVID-19 Vaccine and Heart Attack: Biocon Chief, Karnataka CM get into war of words